ImprimisRx offers a look at three new products in the pipeline
November 14, 2021
ImprimisRx President John Saharek shares an update on a few of the company's latest products during AAO 2021.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Pharmacy
Aerie Pharmaceuticals CEO discusses what's new in the pipeline
March 22, 2022
Raj Kannan, the new CEO of Aerie Pharmaceuticals, talks with Ophthalmology Times' David Hutton about what's coming down the pipeline for Aerie.
.png?w=480&max-h=270&fit=crop&auto=format)
Making the grade: FDA approves first biosimilar product for retinal diseases
November 01, 2021
The FDA has given its approval to Byooviz (ranibizumab-nuna, SB11, Samsung Bioepis Co Inc and Biogen Inc), a biosimilar referencing Lucentis (ranibizumab, Genentech).
Advancement in TED treatment is a bright spot
June 30, 2021
FDA approval of teprotumumab as therapeutic offers hope for patients.
Comparable conscious sedation methods address individual patient needs
April 14, 2021
Sublingual troche sedation represents attractive anesthesia option for specific subset of patients with cataracts.
Investigators uncover health care disparities among US patients
April 02, 2021
Study highlights role of demographic and socioeconomic characteristics in treatment.
Investigators zoom in on future of dry eye treatment
March 02, 2021
Autologous serum eye drops and blood products offer hope to patients.
Visus CEO updates on lead product candidate, 2021 pipeline
January 27, 2021
Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.
Analyzing opioid prescription patterns of US retina specialists
November 16, 2020
Investigators looked at trends by geographic variation in practice patterns, perceptions toward opioids, and patient population
(AAO) Genentech provides update on presentations, product portfolio
November 13, 2020
Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.